News

Search is on for cases of aggressive, ruxolitinib-associated skin cancers


 

AT THE ACMS ANNUAL MEETING

References

“He was already immunosuppressed from his malignancy. He was on hydroxyurea, a drug that’s a cumulative phototoxin, and he’s out in the sun playing golf every day, and then was put on ruxolitinib. But the question we face now is how to try and stop this medication so we can get better treatment for him which will, of course, be very difficult.”

To contribute to Dr. Zwald’s case series, please email her at Fiona.Zwald@gmail.com.

She had no relevant financial disclosures.

msullivan@frontlinemedcom.com

On Twitter @Alz_Gal

Pages

Recommended Reading

Idarucizumab reverses dabigatran’s anticoagulant effects
MDedge Surgery
Study establishes protocol for perioperative dabigatran discontinuation
MDedge Surgery
Surgical bleeding risk ‘remarkable’ with platelet disorders
MDedge Surgery
Dicloxacillin may cut INR levels in warfarin users
MDedge Surgery